Provided by Tiger Trade Technology Pte. Ltd.

Hutchison China Meditech

14.63
+0.48003.39%
Post-market: 14.630.00000.00%19:30 EDT
Volume:78.13K
Turnover:1.15M
Market Cap:2.55B
PE:144.92
High:14.93
Open:14.45
Low:14.45
Close:14.15
52wk High:16.40
52wk Low:9.77
Shares:174.43M
Float Shares:104.00M
Volume Ratio:1.26
T/O Rate:0.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.1010
EPS(LYR):2.60
ROE:1.46%
ROA:-1.24%
PB:2.02
PE(LYR):5.63

Loading ...

Press Release: Poxel Reports First Quarter 2026 Revenue and Provides a Business Update

Dow Jones
·
May 20

Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC

GlobeNewswire
·
May 15

Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026

GlobeNewswire
·
May 11

Edgewise Therapeutics' Update for EDG-7500 Could Boost Shares, RBC Says

MT Newswires Live
·
May 09

Press Release: Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications

Dow Jones
·
May 07

Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

GlobeNewswire
·
May 07

Press Release: Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
May 07

Asure Software Sets May & June 2026 Investor Conference Schedule

GlobeNewswire
·
May 07

Analyst Maintains Buy Rating and $136 Price Target on Aficamten Following Strong Phase 3 ACACIA-HCM Results

TIPRANKS
·
May 06

Press Release: Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital

Dow Jones
·
May 05

Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026

GlobeNewswire
·
May 05

Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

GlobeNewswire
·
Apr 30

Hutchmed Says China Grants Priority Review for Sovleplenib in Autoimmune Hemolytic Anemia

MT Newswires Live
·
Apr 29

HUTCHMED's Sovleplenib NDA for Warm Autoimmune Hemolytic Anemia Accepted in China with Priority Review and Breakthrough Therapy Designation

Stock News
·
Apr 29

Sage launches Sage HCM to connect HR, payroll and finance for mid-market businesses

GlobeNewswire
·
Apr 23

EX3 Accelerates APAC Expansion with Malaysia Growth Milestone and SAP Partnership

prnewswire
·
Apr 21

Market Navigation for April 20, 2026: Announcements and Trading Alerts for Shanghai and Shenzhen Stocks

Deep News
·
Apr 20

Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting

GlobeNewswire
·
Apr 17

Asure Software to Announce First Quarter 2026 Financial Results on April 30, 2026

GlobeNewswire
·
Apr 17

Humanforce Launches Humanforce Connect, the First Operating System for Frontline and Flexible Work

prnewswire
·
Apr 13